Clinical Data ECO 2026: gut hormone signals differ in T1D with obesity Pharmaceutical TechnologyAt ECO 2026, researchers presented a study assessing fasting PYY, ghrelin and GIP levels in T1D patients, with or without obesity.Metabolic & GLP-1Read full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology At ECO 2026, researchers presented a study assessing fasting PYY, ghrelin and GIP levels in T1D patients, with or without obesity. Metabolic & GLP-1 Read full story Post navigation Previous: Zydus to acquire Assertio in $166m dealNext: Regulatory round-up: A month of key FDA approvals for cancer drugs Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026